nor-NOHA HCl | CAS#291758-32-2 | Arginase inhibitor

MedKoo Cat#: 556042 | Name: nor-NOHA HCl

Description:

WARNING: This product is for research use only, not for human or veterinary use.

nor-NOHA, also known as N-Hydroxy-nor-L-Arginine, is an Arginase inhibitor. nor-NOHA induces apoptosis in leukemic cells specifically under hypoxic conditions but CRISPR/Cas9 excludes arginase 2 (ARG2) as the functional target. Nor-NOHA can induce cell apoptosis and inhibit the ability of invasion and migration of HepG2 cells by inhibiting Arg1, which is related with the increase of iNOS expression and the high concentration of NO.

Chemical Structure

nor-NOHA HCl

CAS#291758-32-2 (HCl)

Theoretical Analysis

MedKoo Cat#: 556042

Name: nor-NOHA HCl

CAS#: 291758-32-2 (HCl)

Chemical Formula: C5H14Cl2N4O3

Exact Mass: 0.0000

Molecular Weight: 249.09

Elemental Analysis: C, 24.11; H, 5.67; Cl, 28.46; N, 22.49; O, 19.27

Price and Availability

Size	Price	Availability
25mg	USD 350.00	2 Weeks
50mg	USD 550.00	2 Weeks
100mg	USD 950.00	2 Weeks
200mg	USD 1,650.00	2 Weeks
500mg	USD 2,650.00	2 Weeks
1g	USD 3,650.00	2 Weeks
2g	USD 5,950.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

189302-40-7 (free base) 1140844-63-8 (acetate) 291758-32-2 (HCl) 2250019-93-1 (mono acetate)

Synonym

N-Hydroxy-nor-L-Arginine; H-norArg(delta-OH)-OH; nor-NOHA HCl; nor-NOHA hydrochloride.

IUPAC/Chemical Name

(S,E)-2-amino-4-(2-hydroxyguanidino)butanoic acid dihydrochloride

InChi Key

AKPIIXWPTMFQQJ-QTNFYWBSSA-N

InChi Code

InChI=1S/C5H12N4O3.2ClH/c6-3(4(10)11)1-2-8-5(7)9-12;;/h3,12H,1-2,6H2,(H,10,11)(H3,7,8,9);2*1H/t3-;;/m0../s1

SMILES Code

O=C(O)[C@@H](N)CCN/C(N)=N/O.[H]Cl.[H]Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

arginase has been that of regulating nitric oxide (NO) prodn. by a substrate (L-arginine) competition between arginase and nitric oxide synthase (NOS).

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 249.09 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

This message contains search results from the National Center for Biotechnology Information (NCBI) at the U.S. National Library of Medicine (NLM). Do not reply directly to this message Sent On: Sat Oct 30 13:18:20 2021 Search: nor-NOHA 20 selected items PubMed Results Items 1-20 of 20 (Display the 20 citations in PubMed) 1: Crompton RA, Williams H, Campbell L, Lim HK, Saville C, Ansell DM, Reid A, Wong J, Vardy LA, Hardman MJ, Cruickshank SM. An epidermal-specific role for arginase1 during cutaneous wound repair. J Invest Dermatol. 2021 Oct 25:S0022-202X(21)02288-0. doi: 10.1016/j.jid.2021.09.009. Epub ahead of print. PMID: 34710388. 2: Wang H, Ji J, Zhuang Y, Zhou X, Zhao Y, Zhang X. PMA induces the differentiation of monocytes into immunosuppressive MDSCs. Clin Exp Immunol. 2021 Nov;206(2):216-225. doi: 10.1111/cei.13657. Epub 2021 Sep 9. PMID: 34453319; PMCID: PMC8506123. 3: Mittal A, Wang M, Vidyarthi A, Yanez D, Pizzurro G, Thakral D, Tracy E, Colegio OR. Topical arginase inhibition decreases growth of cutaneous squamous cell carcinoma. Sci Rep. 2021 May 24;11(1):10731. doi: 10.1038/s41598-021-90200-y. PMID: 34031449; PMCID: PMC8144401. 4: André C, Guillaume YC. Development of a new nano arginase HPLC capillary column for the fast screening of arginase inhibitors and evaluation of their binding affinity. J Chromatogr B Analyt Technol Biomed Life Sci. 2021 Jun 15;1175:122751. doi: 10.1016/j.jchromb.2021.122751. Epub 2021 May 1. PMID: 33991957. 5: Scholle MD, Gurard-Levin ZA. Development of a Novel Label-Free and High- Throughput Arginase-1 Assay Using Self-Assembled Monolayer Desorption Ionization Mass Spectrometry. SLAS Discov. 2021 Jul;26(6):775-782. doi: 10.1177/24725552211000677. Epub 2021 Mar 23. PMID: 33754845. 6: Hara M, Torisu K, Tomita K, Kawai Y, Tsuruya K, Nakano T, Kitazono T. Arginase 2 is a mediator of ischemia-reperfusion injury in the kidney through regulation of nitrosative stress. Kidney Int. 2020 Sep;98(3):673-685. doi: 10.1016/j.kint.2020.03.032. Epub 2020 Apr 25. PMID: 32739205. 7: Grobben Y, Uitdehaag JCM, Willemsen-Seegers N, Tabak WWA, de Man J, Buijsman RC, Zaman GJR. Structural insights into human Arginase-1 pH dependence and its inhibition by the small molecule inhibitor CB-1158. J Struct Biol X. 2019 Nov 26;4:100014. doi: 10.1016/j.yjsbx.2019.100014. PMID: 32647818; PMCID: PMC7337048. 8: Azambuja JH, Ludwig N, Yerneni SS, Braganhol E, Whiteside TL. Arginase-1+ Exosomes from Reprogrammed Macrophages Promote Glioblastoma Progression. Int J Mol Sci. 2020 Jun 2;21(11):3990. doi: 10.3390/ijms21113990. PMID: 32498400; PMCID: PMC7312363. 9: Hein TW, Omae T, Xu W, Yoshida A, Kuo L. Role of Arginase in Selective Impairment of Endothelium-Dependent Nitric Oxide Synthase-Mediated Dilation of Retinal Arterioles during Early Diabetes. Invest Ophthalmol Vis Sci. 2020 May 11;61(5):36. doi: 10.1167/iovs.61.5.36. PMID: 32437549; PMCID: PMC7405695. 10: Hannemann J, Roskam TI, Eilermann I, Siques P, Brito J, Böger R. Pre- Analytical and Clinical Validation of a Dried Blood Spot Assay for Asymmetric Dimethylarginine and L-Arginine. J Clin Med. 2020 Apr 9;9(4):1072. doi: 10.3390/jcm9041072. PMID: 32283799; PMCID: PMC7230730. 11: Momma TY, Ottaviani JI. Arginase inhibitor, Nω-hydroxy-L- norarginine, spontaneously releases biologically active NO-like molecule: Limitations for research applications. Free Radic Biol Med. 2020 May 20;152:74-82. doi: 10.1016/j.freeradbiomed.2020.02.033. Epub 2020 Mar 1. PMID: 32131024. 12: Muessig JM, Moellhoff L, Noelle J, Kaya S, Hidalgo Pareja L, Masyuk M, Roden M, Kelm M, Jung C. Poor glycemic control impairs the cardioprotective effects of red blood cells on myocardial ischemia/reperfusion injury. Nitric Oxide. 2020 Apr 1;97:1-10. doi: 10.1016/j.niox.2020.01.008. Epub 2020 Jan 22. PMID: 31981741. 13: Bujor A, Miron A, Luca SV, Skalicka-Wozniak K, Silion M, Trifan A, Girard C, Demougeot C, Totoson P. Vasorelaxant effects of Crataegus pentagyna: Links with arginase inhibition and phenolic profile. J Ethnopharmacol. 2020 Apr 24;252:112559. doi: 10.1016/j.jep.2020.112559. Epub 2020 Jan 11. Erratum in: J Ethnopharmacol. 2021 Jun 12;273:113962. PMID: 31935497. 14: Nahidi S, Gholami E, Taslimi Y, Habibzadeh S, Seyed N, Davarpanah E, Ghanadan A, Rafati S, Taheri T. The outcome of arginase activity inhibition in BALB/c mice hosting Leishmania tropica. Parasite Immunol. 2020 Mar;42(3):e12691. doi: 10.1111/pim.12691. Epub 2020 Jan 7. PMID: 31811772. 15: Avtandilyan N, Javrushyan H, Mamikonyan A, Grigoryan A, Trchounian A. The potential therapeutic effect of NG-hydroxy-nor-L-arginine in 7,12-dimethylbenz(a)anthracene-induced breast cancer in rats. Exp Mol Pathol. 2019 Dec;111:104316. doi: 10.1016/j.yexmp.2019.104316. Epub 2019 Oct 17. PMID: 31629728. 16: Van Zandt MC, Jagdmann GE, Whitehouse DL, Ji M, Savoy J, Potapova O, Cousido-Siah A, Mitschler A, Howard EI, Pyle AM, Podjarny AD. Discovery of N-Substituted 3-Amino-4-(3-boronopropyl)pyrrolidine-3-carboxylic Acids as Highly Potent Third-Generation Inhibitors of Human Arginase I and II. J Med Chem. 2019 Sep 12;62(17):8164-8177. doi: 10.1021/acs.jmedchem.9b00931. Epub 2019 Aug 23. PMID: 31408339. 17: Hein TW, Xu X, Ren Y, Xu W, Tsai SH, Thengchaisri N, Kuo L. Requisite roles of LOX-1, JNK, and arginase in diabetes-induced endothelial vasodilator dysfunction of porcine coronary arterioles. J Mol Cell Cardiol. 2019 Jun;131:82-90. doi: 10.1016/j.yjmcc.2019.04.015. Epub 2019 Apr 20. PMID: 31015037; PMCID: PMC6911365. 18: Bordy R, Quirié A, Marie C, Wendling D, Totoson P, Demougeot C. Vascular Arginase Is a Relevant Target to Improve Cerebrovascular Endothelial Dysfunction in Rheumatoid Arthritis: Evidence from the Model of Adjuvant-Induced Arthritis. Transl Stroke Res. 2020 Feb;11(1):4-15. doi: 10.1007/s12975-019-00699-7. Epub 2019 Mar 18. PMID: 30887278. 19: Ding LY, Wang YF, Shen YZ, Zhou G, Zhang X, Wang MZ, Loor JJ, Zhang J. Effects of arginase inhibition via jugular infusion of Nω-hydroxy- nor-l-arginine on metabolic and immune indices in lactating dairy cows. J Dairy Sci. 2019 Apr;102(4):3310-3320. doi: 10.3168/jds.2018-14879. Epub 2019 Feb 7. PMID: 30738683. 20: Meade RD, Fujii N, McGarr GW, Alexander LM, Boulay P, Sigal RJ, Kenny GP. Local arginase inhibition does not modulate cutaneous vasodilation or sweating in young and older men during exercise. J Appl Physiol (1985). 2019 Apr 1;126(4):1129-1137. doi: 10.1152/japplphysiol.00657.2018. Epub 2019 Jan 17. PMID: 30653418; PMCID: PMC6485684.

View History

STP0404

MedKoo CAT#: 466226

CAS#: unknown